Navigation Links
Cardiac Science Releases New Cardiac Rehabilitation System
Date:10/2/2007

Enhances connectivity to HIS and EMR solutions

BOTHELL, Wash., Oct. 2 /PRNewswire-FirstCall/ -- Cardiac Science Corporation, (Nasdaq: CSCX), a global leader in advanced cardiac monitoring and defibrillation products, announced today the launch of the Quinton Q-Tel RMS(R) 3.0. This significant advance to the trusted Quinton line of cardiac rehabilitation systems offers several connectivity upgrades and workflow advancements to enable the best possible treatment decisions in cardiac rehabilitation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO)

Some of the Q-Tel 3.0 key advancements include:

-- Bi-directional connectivity to a hospital's EMR and HIS system.

-- Improved tracking of HIPAA compliance requirements through user

activity logs.

-- Session Recovery advancements to prevent the loss of patient data due

to power interruption or application error.

-- Q-Tel Pocket Assistant for wireless session management, enabling users

to customize data entry parameters and formats for resting, exercise

and recovery data by program type.

"Quinton Q-Tel connects the clinician to the enterprise EMR, the patient, the medical staff and the latest technology," said Rene Mitchell, director of diagnostic marketing at Cardiac Science. "In addition to offering nurses and exercise physiologists the reliable, high-performance rehab technology they have come to expect from the Q-Tel system, Q-Tel 3.0 improves workflow efficiency with enhanced connectivity, allowing the rehab department to connect to the hospital's HIS and EMR system. These enhan
'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Gene HPA-2 Met linked to cardiac arrest
3. Defibrillators In Public Places Will Help Cardiac Patients
4. Supplement helps cardiac surgery
5. Cardiac diseases develop early
6. Latest device for cardiac revival under test
7. Bone marrow stem cells may help repair cardiac tissues
8. Heart problems detected better with a Cardiac MRI
9. Cardiac events better treated with intense cholesterol-lowering regime
10. Sudden Cardiac Death due to inherited Heart Disease
11. Vasopressin Found To Boost Survival In Sudden Cardiac arrest

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, CHICA...nited States House of Representatives passed by a ...lation that would strengthen Medicare for seniors ... prices millions of Americans out of affordable he...
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, BALTI... Tonight the United States House of Representative...hat would strengthen Medicare for seniors and end ...millions of Americans out of affordable health cov...
(Date:11/7/2009)...ON, Nov. 7 Karen Ignagn... Plans (AHIP), released the following statement to...lans strongly support comprehensive health care re...y proposing a complete overhaul of how health insu...guaranteed coverage, elimination of pre-existing c...
(Date:11/7/2009)... Nov. 7, The American M...njamin Rush Award for Citizenship and Community Se...from Chicago, IL. The award recognizes physicians ...call of duty to make an outstanding public service...received the award today during the opening sessio...
(Date:11/7/2009)...yn T. Coleman (CT), David A. Cook (GA), Louis J. G... (LA) Honored ,, CHICAGO, Nov. 7 /PRNewswire-U...A) today presented five medical society executive ...tributions to the goals and ideals of the medical ... semi-annual policy making meeting in Houston. ,...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA Honors Medical Society Executives 2
...he Prescription Drug User Fee Act (PDUFA) user fee...ry 18, 2008 -, YARDLEY, Pa., Sept. 20 Tibotec Ph...ug Application (NDA) for TMC125,(etravirine), an i...stration (FDA). The Prescription Drug User Fee,Act...
...LIN, N.J., Sept. 20 SyntheMed, Inc. (OTC,Bulletin...he development,and commercialization of anti-adhes...t the Circulatory System Devices Advisory Panel of...,likely to need secondary open heart surgery. The ...
...phyX(TM) receives FDA clearance, REDMOND, Wash., ... EsophyX(TM) device for performing Transoral Incis...ing gastroesophageal reflux,disease has received F...pleted yesterday under general anesthesia,transora...
...BOSTON Since the days of Hippocrates, people have ...seasons. More recently, researchers have learned t...seasonality, are often related to the weather. In ... Department of Public Heath and Family Medicine at...
...(Washington) Expressions of deep concern and disa...authorization will go forward without addressing s...for Medicare beneficiaries were sent today to cong...nal medicine physicians and medical student member...
...ndation Duped By Overseas Supplier, WAKEFIELD, Ma...tion established to support cancer-fighting resear...ng due to high lead levels the jewelry it,distribu... contain lead. When Friends of Mel recently learne...
Other Medicine News:Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 2Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 3Health News:FDA Panel Recommends Approval of SyntheMed's REPEL-CV(R) Adhesion Barrier for Pediatric Patients 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 3Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 4Health News:Mathematics might save you a trip to the ER 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 3Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 2Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 3
(Date:11/6/2009)..., Nov. 6 Caraco Pharmace...aunched ketorolac tromethamine ophthalmic solution... and Drug Administration (FDA) for Sun Pharma,s Ab...Acular® opthalmic solution on the first day f...olac is therapeutically equivalent to Acular®...
(Date:11/6/2009)...IS, November 6 , - Trial ...lid for the,Treatment of Multi-Resistant Staphyloc... a speciality pharmaceutical company focused on th...esigned to overcome the significant global,problem... most advanced oral,antibacterial NXL103 (floprist...
(Date:11/5/2009)...GO, Nov. 5 Althea Technologies, I...turing services for biopharmaceutical products ann...lopment to the company,s platform of services, whi...es Matsuura, Director of Formulation Development. ...ion and analytical scientists, along with new labo...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Partnership to accelerate Trudeau Institute discoveries to patient care 8711 1Partnership to accelerate Trudeau Institute discoveries to patient care 8711 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 1Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 3WWII Veterans Compete in National Veterans Golden Age Games 47813 1WWII Veterans Compete in National Veterans Golden Age Games 47813 2
...NTA, Dec. 11 The Arthritis Foundation,the leading...llion,Americans living with arthritis, today annou...eters of Enbrel (R) (etanercept), will be the,nati... (R)., "The Arthritis Foundation hosts hundreds o...to prevent, control and cure arthritis, the,nation...
...CETON, N.J. and FOSTER CITY, Calif., Dec. 11 /PRNe...(NYSE: BMY ) and Gilead Sciences, Inc.,(Nasdaq: ...ze ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 ... for the treatment of virologically suppressed adu... approval by the European,Commission. If approved,...
Other Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8
Assay Development
Custom Conjugation
Iso-Electric Determination Kit
Rabbit Anti-Goat IgG (H & L) Antibody, Colloidal Gold Conjugated, 50 OD
Medicine Products: